LIFE Stock Price, aTyr Pharma Inc Quote, Chart

Market Summary

USD2.00+0.07

Delayed

3.63%

LIFE Stock Price

View Fullscreen

LIFE RSI Chart

LIFE Valuation

Market Cap

138.0M

Price/Earnings (Trailing)

-2.56

Price/Sales (Trailing)

391

EV/EBITDA

-2.65

Price/Free Cashflow

-2.38

LIFE Price/Sales (Trailing)

LIFE Profitability

EBT Margin

-14276.20%

Return on Equity

-63.99%

Return on Assets

-47.62%

Free Cashflow Yield

-42.02%

LIFE Fundamentals

LIFE Revenue

Revenue (TTM)

353.0K

Rev. Growth (Qtr)

-100%

LIFE Earnings

Earnings (TTM)

-53.9M

Earnings Growth (Yr)

-29.69%

Earnings Growth (Qtr)

-4.79%

Breaking Down LIFE Revenue

Last 7 days

18.3%

Last 30 days

25.8%

Last 90 days

-1.0%

Trailing 12 Months

-17.4%

How does LIFE drawdown profile look like?

LIFE Financial Health

Current Ratio

6.07

Debt/Equity

0.03

Debt/Cashflow

-20.06

LIFE Investor Care

Shares Dilution (1Y)

27.11%

Diluted EPS (TTM)

-0.89

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	7.0M	0	3.7M	353.0K
2022	10.4M	10.4M	10.4M	10.4M
2021	0	0	0	10.4M
2020	2.9M	5.4M	7.9M	10.5M
2019	0	0	0	422.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of aTyr Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 06, 2024	broadfoot jill marie	sold	-2,687	1.69	-1,590	chief financial officer
Feb 05, 2024	broadfoot jill marie	acquired	-	-	3,750	chief financial officer
Feb 05, 2024	shukla sanjay	acquired	-	-	10,375	president and ceo
Feb 05, 2024	denyes nancy	acquired	-	-	2,688	general counsel
Dec 12, 2023	shukla sanjay	bought	14,136	1.178	12,000	president and ceo
Dec 11, 2023	shukla sanjay	bought	3,510	1.17	3,000	president and ceo
Nov 13, 2023	shukla sanjay	bought	15,085	1.111	13,578	president and ceo
Nov 10, 2023	shukla sanjay	bought	1,618	1.138	1,422	president and ceo
Jul 28, 2023	shukla sanjay	bought	30,223	2.0149	15,000	president and ceo
May 17, 2023	coughlin timothy	gifted	-	-	-6,000	-

Which funds bought or sold LIFE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	121,173	121,173	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	309,307	309,307	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	unchanged	-	254,412	918,711	0.10%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-61.99	-17,747	19,672	-%
May 15, 2024	Royal Bank of Canada	reduced	-83.00	-98,000	30,000	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	51.31	221,170	423,604	-%
May 15, 2024	CITADEL ADVISORS LLC	added	8.54	1,238,950	3,711,520	-%
May 15, 2024	STATE STREET CORP	unchanged	-	90,077	325,276	-%
May 15, 2024	MORGAN STANLEY	added	23.83	15,999	38,450	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	4.99	94,791	304,541	-%

Are Funds Buying or Selling LIFE?

Are funds buying LIFE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LIFE

No. of Funds

Unveiling aTyr Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	lytton laurence w	1.0%	585,013	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	0.8%	482,258	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 18, 2024	federated hermes, inc.	17.37%	10,169,600	SC 13G/A
Jan 02, 2024	logos global management lp	9.9%	5,800,000	SC 13G
Feb 22, 2023	lytton laurence w	8.7%	4,440,188	SC 13G
Feb 17, 2023	stonepine capital management, llc	8.9%	4,569,433	SC 13G/A
Feb 14, 2023	venrock healthcare capital partners ii, l.p.	4.0%	1,171,436	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 01, 2023	federated hermes, inc.	18.03%	5,231,600	SC 13G/A

Recent SEC filings of aTyr Pharma Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	8-K	Current Report
May 02, 2024	10-Q	Quarterly Report
Apr 05, 2024	DEFA14A	DEFA14A
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	ARS	ARS
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to aTyr Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

aTyr Pharma Inc News

Latest updates

aTyr Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-	235,000	-	353,000	595,857	838,714	1,081,571	1,324,429	1,567,286	1,810,143	2,053,000	148,000	189,000	8,065,000	4,124,500	184,000	94,000
Operating Expenses	5.7%	16,871,000	15,959,000	12,968,000	12,787,000	18,336,000	13,492,000	12,584,000	12,378,000	8,640,000	6,993,000	6,660,000	6,507,000	6,206,000	6,106,000	5,682,000	5,735,000
S&GA Expenses	-100.0%	-	3,204,000	2,649,000	3,408,000	3,426,000	3,625,000	3,449,000	3,482,000	2,685,000	2,295,000	2,044,000	2,146,000	2,590,000	2,516,000	1,883,000	2,421,000
R&D Expenses	4.8%	13,364,000	12,755,000	10,319,000	9,379,000	14,910,000	9,867,000	9,135,000	8,896,000	5,955,000	4,698,000	4,616,000	4,361,000	3,616,000	3,590,000	3,799,000	3,314,000
EBITDA Margin	0.2%	-140	-140	-12.10	-6.40	-4.34	-3.22	-3.20	-3.19	-3.19	-	-	-	-	-	-	-
Interest Expenses	-2.6%	38,000	39,000	39,000	46,000	54,000	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	0%	-142	-142	-12.26	-6.44	-4.37	-3.25	-3.24	-3.24	-3.23	-	-	-	-	-	-	-
Net Income	-4.8%	-15,500,000	-14,792,000	-11,300,000	-11,952,000	-7,520,000	-13,244,000	-12,421,000	-12,154,000	-8,556,500	-4,931,000	-6,599,000	-6,447,000	1,752,000	-5,973,000	-5,645,000	-5,848,000
Net Income Margin	-7.0%	-152	-142	-11.66	-6.41	-4.37	-4.46	-3.92	-3.72	-3.23	-	-	-	-	-	-	-
Free Cashflow	-102.2%	-22,397,000	-11,079,000	-10,116,000	-1,836,000	-11,488,000	-12,707,000	-9,170,000	-10,162,000	-8,104,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-6.1%	113	121	125	133	137	96.00	96.00	96.00	105	116	124	49.00	55.00	39.00	42.00	48.00	54.00	36.00	44.00	49.00	50.00
Current Assets	-5.9%	97.00	103	107	114	119	81.00	85.00	93.00	103	114	122	46.00	52.00	36.00	38.00	44.00	50.00	32.00	39.00	44.00	45.00
Cash Equivalents	-69.8%	7.00	23.00	10.00	12.00	21.00	10.00	18.00	8.00	8.00	2.00	60.00	2.00	13.00	17.00	18.00	22.00	39.00	9.00	17.00	15.00	13.00
Net PPE	-3.2%	5.00	6.00	6.00	6.00	5.00	3.00	1.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00
Current Liabilities	-2.7%	16.00	16.00	13.00	12.00	14.00	14.00	11.00	9.00	6.00	6.00	6.00	7.00	4.00	6.00	8.00	10.00	10.00	13.00	12.00	11.00	11.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	5.00	6.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	5.00	7.00	9.00	8.00	8.00	8.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	5.00	6.00
Shareholder's Equity	-7.0%	84.00	91.00	98.00	106	110	71.00	77.00	86.00	98.00	109	117	41.00	50.00	31.00	32.00	36.00	42.00	21.00	27.00	30.00	29.00
Retained Earnings	-3.3%	-483	-468	-453	-441	-429	-417	-410	-396	-384	-372	-363	-356	-345	-338	-333	-327	-320	-322	-316	-310	-304
Additional Paid-In Capital	1.7%	568	559	552	548	540	490	488	484	484	482	481	397	395	370	366	363	363	344	343	341	334
Shares Outstanding	8.0%	68.00	63.00	59.00	57.00	53.00	29.00	29.00	28.00	28.00	19.00	18.00	15.00	-	-	-	-	-	-	-	-	-
Minority Interest	2.1%	-0.18	-0.19	-0.19	-0.18	-0.18	-0.18	-0.18	-0.18	-0.18	-0.17	-0.17	-0.17	-0.17	-0.17	-0.16	-0.16	-0.16	-0.16	-	-	-
Float	-	-	-	-	121	-	-	-	77.00	-	-	-	76.00	-	-	-	25.00	-	-	-	10.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-102.3%	-22,380	-11,062	-9,559	-12,010	-590	-10,369	-12,281	-9,117	-10,119	-8,086	-11,470	-7,692	-5,827	-5,401	-5,555	-6,403	2,058	-4,916	-4,253	-4,821	-6,023
Share Based Compensation	-100.0%	-	659	664	658	619	605	615	517	417	414	442	398	360	340	324	378	423	425	278	509	571
Cashflow From Investing	-107.6%	-1,356	17,818	4,383	-4,156	-38,172	1,999	20,649	9,971	14,626	-49,348	-14,849	-3,974	-23,395	3,203	1,740	-9,449	11,406	-1,220	7,209	2,291	-3,355
Cashflow From Financing	28.1%	7,730	6,034	2,682	8,018	49,496	918	3,013	39.00	1,481	28.00	83,869	1,271	24,857	999	334	-1,969	16,779	-1,995	-122	4,072	-619

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LIFE Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 235	$ 0
Revenue, Product and Service [Extensible Enumeration]	License and Collaboration Revenues [Member]	License and Collaboration Revenues [Member]
Operating expenses:
Research and development	$ 13,364	$ 9,379
General and administrative	3,507	3,408
Total operating expenses	16,871	12,787
Loss from operations	(16,636)	(12,787)
Total other income (expense), net	1,149	835
Consolidated net loss	(15,487)	(11,952)
Net (gain) loss attributable to noncontrolling interest in Pangu BioPharma Limited	(4)	1
Net loss attributable to aTyr Pharma, Inc.	$ (15,491)	$ (11,951)
Net loss per share - basic	$ (0.23)	$ (0.29)
Net loss per share - diluted	$ (0.23)	$ (0.29)
Shares used in computing net loss per share, basic	66,080,593	41,897,706
Shares used in computing net loss per share, diluted	66,080,593	41,897,706

LIFE Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,808	$ 22,544
Available-for-sale investments	77,688	75,622
Other receivables	2,476	2,436
Prepaid expenses	9,944	2,390
Total current assets	96,916	102,992
Restricted cash	3,214	3,484
Property and equipment, net	5,353	5,531
Operating lease, right-of-use assets	5,999	6,727
Financing lease, right-of-use assets	1,639	1,788
Other assets	130	131
Total assets	113,251	120,653
Current liabilities:
Accounts payable	4,893	3,529
Accrued expenses	9,950	11,559
Current portion of operating lease liability	629	831
Current portion of financing lease liability	507	497
Total current liabilities	15,979	16,416
Long-term operating lease liability, net of current portion	11,693	12,339
Long-term financing lease liability, net of current portion	1,297	1,428
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of March 31, 2024 (unaudited) and December 31, 2023; no shares issued or outstanding as of March 31, 2024 (unaudited) and December 31, 2023
Common stock, $0.001 par value per share; 170,000,000 authorized shares as of March 31, 2024 (unaudited) and December 31, 2023; issued and outstanding shares - 68,354,033 as of March 31, 2024 (unaudited) and 63,286,404 as of December 31, 2023	68	63
Additional paid-in capital	568,070	558,692
Accumulated other comprehensive loss	(158)	(74)
Accumulated deficit	(483,514)	(468,023)
Total aTyr Pharma stockholders’ equity	84,466	90,658
Noncontrolling interest in Pangu BioPharma Limited	(184)	(188)
Total stockholders' equity	84,282	90,470
Total liabilities and stockholders’ equity	$ 113,251	$ 120,653

About aTyr Pharma Inc

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

CEO	Dr. Sanjay S. Shukla M.D., M.S.
WEBSITE	atyrpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	65

aTyr Pharma Inc Frequently Asked Questions

What is the ticker symbol for aTyr Pharma Inc? What does LIFE stand for in stocks?

LIFE is the stock ticker symbol of aTyr Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of aTyr Pharma Inc (LIFE)?

As of Fri May 17 2024, market cap of aTyr Pharma Inc is 138.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIFE stock?

You can check LIFE's fair value in chart for subscribers.

What is the fair value of LIFE stock?

You can check LIFE's fair value in chart for subscribers. The fair value of aTyr Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of aTyr Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LIFE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is aTyr Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether LIFE is over valued or under valued. Whether aTyr Pharma Inc is cheap or expensive depends on the assumptions which impact aTyr Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIFE.

What is aTyr Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LIFE's PE ratio (Price to Earnings) is -2.56 and Price to Sales (PS) ratio is 391. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIFE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on aTyr Pharma Inc's stock?

In the past 10 years, aTyr Pharma Inc has provided -0.473 (multiply by 100 for percentage) rate of return.